PharmaEssentia's Ropeginterferon Shows Promising Results in Phase 3 Trial for Essential Thrombocythemia
PharmaEssentia will present positive Phase 3 SURPASS-ET trial results showing ropeginterferon alfa-2b-njft achieved significantly higher durable clinical response rates compared to anagrelide (42.9% vs. 6.0%; p=0.0001) in essential thrombocythemia patients.
Ropeginterferon Alfa-2b Shows Promise as Second-Line Treatment for High-Risk Essential Thrombocythemia
• A Phase 3 trial (SURPASS-ET) is evaluating Ropeginterferon alfa-2b (P1101) versus anagrelide in high-risk essential thrombocythemia (ET) patients intolerant or resistant to hydroxyurea. • The primary endpoint is durable modified European LeukemiaNet composite response at 9 and 12 months. • Initial data from 101 randomized patients across 58 global sites show the trial is proceeding as planned, with no need for intervention identified by the DSMB. • This study could provide the first evidence comparing P1101 with anagrelide, the only approved second-line treatment option for ET.